Pendrell Corp Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013
Operating activities:
Net income (loss) including noncontrolling interest
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Stock-based compensation
Amortization of prepaid compensation from Ovidian acquisition
Amortization of intangible assets
Impairment of intangible assets and goodwill
Depreciation
Unrealized foreign exchange (gains) losses
Non-cash cost of patents monetized
Loss associated with the abandonment and/or disposition of patents
Loss on the disposition of property
Other
Other changes in certain assets and liabilities:
Other receivables
Accounts receivable, current and non-current
Income tax receivable, net
Prepaid expenses and other current/non-current assets
Accounts payable
Accrued expenses and other current/non-current liabilities

Net cash used in operating activities
Accrued expenses and other current liabilities
Other non-current liabilities

Net cash provided by (used in) operating activities
Investing activities:
Payment received on note receivable
Sale of noncontrolling interest in subsidiary
Purchases of property in service and intangible assets
Proceeds associated with disposition of property
Acquisition of controlling interest in Provitro, net of cash acquired
Net cash provided by (used in) investing activities

Financing activities:
Repurchase of Class A common stock
Cash dividend paid
Payment of statutory taxes for stock awards
Net cash provided by (used in) financing activities
Proceeds from exercise of stock options
Payment of accrued obligations for purchased intangible assets
Purchase of noncontrolling interest in Provitro Bioscience LLC
Net cash used in financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents—beginning of period
Cash and cash equivalents—end of period
Supplemental disclosures:
Income taxes paid
Income taxes received
Supplemental disclosure of non-cash investing and financing activities:
Accrued obligations for purchases of property and intangible assets
Note receivable for disposition of property

Comments